3-[1-(4-chlorophenyl)cyclo pentyl]-5,6,7,8,9,10-hexahydro[1,2,4]triazolo [4,3-a] azocine | 633316-52-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[1-(4-chlorophenyl)cyclo pentyl]-5,6,7,8,9,10-hexahydro[1,2,4]triazolo [4,3-a] azocine
• 英文别名: 3-[1-(4-Chlorophenyl)cyclopentyl]-5,6,7,8,9,10-hexahydro-[1,2,4]triazolo[4,3-a]azocine
• CAS: 633316-52-6
• 化学式: C₁₉H₂₄ClN₃
• 分子量: 329.873
• InChiKey: BFZWVIYEQOFWDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  8-methoxy-2,3,4,5,6,7-hexahydroazocine 、 1-(4-氯苯基)-1-环戊烷甲酸 在 fluoro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate 、 肼 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 13.0h， 生成 3-[1-(4-chlorophenyl)cyclo pentyl]-5,6,7,8,9,10-hexahydro[1,2,4]triazolo [4,3-a] azocine
  参考文献：
  名称：

  [EN] 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA
  [FR] INHIBITEURS DE LA 11-BETA-HYDROXYSTEROIDE DESHYDROGENASE 1 UTILISABLES POUR LE TRAITEMENT DU DIABETE, DE L'OBESITE ET DE LA DYSLIPIDEMIE

  摘要：

  公开号：

  WO2003104207A3

文献信息

• Phenylcyclobutyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type I
  作者：Yuping Zhu、Steven H. Olson、Donald Graham、Gool Patel、Anne Hermanowski-Vosatka、Steven Mundt、Kashmira Shah、Marty Springer、Rolf Thieringer、Samuel Wright、Jianying Xiao、Hratch Zokian、Jasminka Dragovic、James M. Balkovec

  DOI：10.1016/j.bmcl.2008.04.014

  日期：2008.6

  3-(Phenylcyclobutyl)-1,2,4-triazoles were identified as selective inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1). These were active both in vitro and in an in vivo mouse pharmacodynamic (PD) model. Fluorine substitution of the cyclobutane ring improved the pharmacokinetic profile significantly. The synthesis and structure-activity relationships are presented. (c) 2008 Elsevier Ltd. All rights reserved.
• 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1532122B1

  公开（公告）日：2011-12-14
• US7179802B2
  申请人：——

  公开号：US7179802B2

  公开（公告）日：2007-02-20
• [EN] INHIBITION OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 FOR OCULAR NEUROPROTECTION<br/>[FR] INHIBITION DE LA 11 BÊTA-HYDROXYSTÉROÏDE DÉHYDROGÉNASE DE TYPE 1 POUR UNE NEUROPROTECTION OCULAIRE
  申请人：BAUSCH & LOMB

  公开号：WO2009073460A2

  公开（公告）日：2009-06-11

  A composition comprises a material capable of controlling a level of cortisol in an ocular environment for effecting ocular neuroprotection in subjects in risk of developing or worsening an ocular neurodegenerative condition. Such a composition is injected into or implanted in the subject's posterior segment to provide such neuroprotection.
• [EN] 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA<br/>[FR] INHIBITEURS DE LA 11-BETA-HYDROXYSTEROIDE DESHYDROGENASE 1 UTILISABLES POUR LE TRAITEMENT DU DIABETE, DE L'OBESITE ET DE LA DYSLIPIDEMIE
  申请人：——

  公开号：WO2003104207A3

  公开（公告）日：2004-03-25